IL6 and amyloidosis: Other recent case reports have shown the efficacy of an IL-6 inhibitor in clinical practice for colchicine-resistant FMF or secondary amyloidosis in FMF patients.19–22 Taken together, our data support the notion of IL-6 as a main inflammatory cytokine in FMF and, thus, as a promising target in this disease.